Generalized chest CT and lab curves throughout the course of COVID-19

Michael T. Kassin1,3,16, Nicole Varble1,2,16, Maxime Blain1,16, Sheng Xu1, Evrim B. Turkbey3, Stephanie Harmon4,5,14, Dong Yang6, Ziyue Xu6, Holger Roth6, Daguang Xu6, Mona Flores7, Amel Amalou1, Kaiyun Sun8, Sameer Kadi9, Francesca Patella10, Maurizio Cariati10, Alice Scarabelli12, Elvira Stellato12, Anna Maria Ierardi13, Gianpaolo Carrafiello11, Peng An13, Baris Turkbey4,14 & Bradford J. Wood1,3,4,15

A better understanding of temporal relationships between chest CT and labs may provide a reference for disease severity over the disease course. Generalized curves of lung opacity volume and density over time can be used as standardized references from well before symptoms develop to over a month after recovery, when residual lung opacities remain. 739 patients with COVID-19 underwent CT and RT-PCR in an outbreak setting between January 21st and April 12th, 2020. 29 of 739 patients had serial exams (121 CTs and 279 laboratory measurements) over 50 ± 16 days, with an average of 4.2 sequential CTs each. Sequential volumes of total lung, overall opacity and opacity subtypes (ground glass opacity [GGO] and consolidation) were extracted using deep learning and manual segmentation. Generalized temporal curves of CT and laboratory measurements were correlated. Lung opacities appeared 3.4 ± 2.2 days prior to symptom onset. Opacity peaked 1 day after symptom onset. GGO onset was earlier and resolved later than consolidation. Lactate dehydrogenase, and C-reactive protein peaked earlier than procalcitonin and leukopenia. The temporal relationships of quantitative CT features and clinical labs have distinctive patterns and peaks in relation to symptom onset, which may inform early clinical course in patients with mild COVID-19 pneumonia, or may shed light upon chronic lung effects or mechanisms of medical countermeasures in clinical trials.

Abbreviations

Alb  Albumin
ALT  Alanine aminotransferase
APTT  Activated partial thromboplastin time
AST  Aspartate aminotransferase
BUN  Blood urea nitrogen
CRP  C-reactive protein
GGO  Ground-glass opacity
Hb  Hemoglobin
LDH  Lactate dehydrogenase
PCT  Procalcitonin

1Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2Philips Research North America, Cambridge, MA 02141, USA. 3Radiology and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892-1182, USA. 4National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 5Clinical Research Directorate, Frederick National Laboratory for Cancer Research, NCI, Frederick, MD 21702, USA. 6NVIDIA Corporation, Bethesda, MD 20892, USA. 7NVIDIA Corporation, Santa Clara, CA 95051, USA. 8Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA. 9Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. 10Diagnostic and Interventional Radiology Service, ASST Santi Paolo e Carlo, Milan, Italy. 11Department of Radiology and Department of Health Sciences, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milano, 20122 Milan, Italy. 12Department of Radiology, Xiangyang NO. 1 People’s Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441000, China. 13Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 14National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, USA. 15These authors contributed equally: Michael T. Kassin, Nicole Varble, and Maxime Blain. *email: bwood@nih.gov
The role of chest Computed Tomography (CT) in the SARS-CoV-2 pandemic is highly dependent upon local practice patterns and available resources. Scarce data are available on the clinical or research utility of applying tools prospectively for quantitative metrics in patients presenting with pre-symptomatic coronavirus disease 2019 (COVID-19) opacities. The role of imaging in COVID-19 is ill-defined, perhaps in part due to a lack of widespread uniform use, which limits size and availability of data. Although rational, the World Health Organization (WHO) guidance for chest imaging for COVID-19 is based on expert opinion and low-certainty evidence. Additional evidence would thus be welcome regarding its clinical utility.

The lower sensitivity of RT-PCR in early and pre-symptomatic disease as well as imperfect and variable turn around times highlights the potential impact of additional tests with immediate readouts, such as targeted CT in high risk exposed populations. The cohort presented here showed pre-symptomatic CT findings, which adds experiential evidence towards support of the feasibility of CT utility. Although no major therapeutic or vaccine clinical trials implement CT response criteria, a standardized CT quantification tool could possibly detect relevant signals of response or early disease modulation after medical countermeasures. Specifically, the number of affected lobes, extent of well aerated lung, or consolidation at baseline chest CT may predict outcomes in selected populations. Quantification of CT opacities mirrors clinical severity in patients with COVID-19, however standardized, automated and validated assessment tools have not been widely applied to clinical practice nor to clinical trials of COVID-19 therapeutics.

Prior work has evaluated the temporal dynamics of CT features in patients with COVID-19, however, thus far has been focused on post-symptomatic timepoints. Far less is known about the CT appearance in the pre-symptomatic period, nor how this relates to subsequent overall course of the disease. Knowledge of the typical chronology and sequence of the lung opacity volumes and subtypes may inform treatment decisions. Further, deviations from expected patterns before or after symptom onset may carry prognostic or early treatment implications. Ground glass opacities (GGO) are the most common and typical feature on chest CT in patients with COVID-19, however, opacity type and pre-symptomatic CT findings remain incompletely defined.

Quantitative analysis of sequential CTs over time may characterize COVID-19 and better inform efforts to develop drugs or to assess response longitudinally over the course of a hospitalization or in chronic disease. In this study we aimed to evaluate the dynamics of chest CT opacity subtypes in COVID-19 before and after symptom onset. Additionally, the dynamic correlation of symptoms, laboratory data, and CT opacity metrics over the course of infection may provide a standardized reference.

Results

Descriptive CT findings. In total, 121 chest CTs were analyzed from 29 patients. Each patient had an average of 4.2 ± 1.5 CTs (range 2–8 CTs). COVID-19 related opacity was present in all patients at some point during infection and opacities were present in 87% of the CTs (105/121). The main opacity subtype encountered was GGO (84%, 102/121), followed by consolidation (59%, 71/121), atelectasis (27%, 33/121), sub-pleural reticulations (10%, 12/121), and crazy paving (7%, 8/121). Pleural effusion was noted in 10% (12/121).

Both GGOs and consolidation were present on initial CT in all patients. A majority of lung opacity volume was classified as GGO (3.6 ± 0.4.0% of lung volume and 87% of all opacity volume). The maximum percent lung involvement was found 0.6 ± 3.1 days after symptom onset. Similarly, the maximum percent involvement of GGOs was found 0.7 ± 4.1 days after symptom onset. The maximum percent involvement of consolidation was found slightly later, at 1.3 ± 1.3 days after symptom onset. At its peak, percentage lung involvement was 6.3 ± 5.0%. Peak GGO and consolidation percentages were 5.1 ± 4.5% and 1.9 ± 1.2%, respectively. Whole lung and opacity subtype segmentations over time were reconstructed and visualized in Fig. 1.

Dynamic curves for percent lung opacity. Dynamic curves for percent COVID-19 lung opacity in this population demonstrated the disease course on CT over time (Fig. 2, Table 1). Standard deviations are visually appreciated on detailed curves that define the range of the data with upper and lower bounds (Fig. 2b). Individual patient curves are displayed in Supplemental Figure S1. CT data resides in a public repository "The Cancer Imaging Archive" (https://www.cancerimagingarchive.net/).

Lung opacities were observed an average of 3.4 ± 2.2 days prior to symptom onset (maximum seven days). Both GGOs and consolidation were present on initial CT in all patients. A majority of lung opacity volume was classified as GGO (3.6 ± 0.4.0% of lung volume and 87% of all opacity volume). The maximum percent lung involvement was found 0.6 ± 3.1 days after symptoms onset. Similarly, the maximum percent involvement of GGOs was found 0.7 ± 4.1 days after symptom onset. The maximum percent involvement of consolidation was found slightly later, at 1.3 ± 1.3 days after symptom onset. At its peak, percentage lung involvement was 6.3 ± 5.0%. Peak GGO and consolidation percentages were 5.1 ± 4.5% and 1.9 ± 1.2%, respectively. Whole lung and opacity subtype segmentations over time were reconstructed and visualized in Fig. 3.

Opacities (primarily GGO) persisted in a diminished fashion on the last CT (in 14 of 29 patients), with an overall percent lung opacity average of 1.1 ± 2.5% at an average of 46 ± 13 days after symptom onset. The percentage of GGO and consolidation involvement decreased by half of the peak 25 and 6 days later, respectively. At the
last follow-up, GGOs accounted for 1.0 ± 2.3% of the lung 44 ± 17 days after symptom onset and consolidation accounted for 0.1 ± 0.1% at 33 ± 19 days after symptom onset.

**Dynamic curves for COVID-19 lesion attenuation.** Dynamic curves for lesion attenuation during the disease time course were generated (Fig. 4a, Table 2). Standard deviations on detailed curves defined the range of the data with upper and lower bounds (Supplemental Figure S2). Data was extrapolated to the attenuation of the healthy lung (−862 ± 56 HU). Only three data points were used to generate the dynamic consolidation attenuation curve as it was less prevalent. The maximum attenuation of the overall opacities occurred the same day of symptom onset (0.0 ± 3.1 days). The maximum GGO attenuation occurred just before symptom onset at −0.2 ± 3.4 days, while consolidation attenuation peaked later at 1.6 ± 5.1 days.

**Dynamic curves for laboratory measurements.** From all laboratory measurements, procalcitonin (PCT), white blood cell count (WBC), lactate dehydrogenase (LDH), and c-reactive protein (CRP) were found to have similar dynamic curves to percent lung opacity (increase after infection, sharp peak, and decline) and were selected for demonstration of the curves. The average time between the first laboratory test to last laboratory test was 36 ± 22 days. In total, PCT and WBC were measured an average of 3.6 ± 1.3 times per patient. LDH and CRP were measured a total of 30 and 37 times respectively with an average of 1.2 ± 1.0 measurements per patient for both.

The normalized curves for PCT, WBC (inverted), LDH, and CRP over time were generated (Fig. 4b, source data Table 3). Standard deviations on detailed curves define the range of the data with upper and lower bounds (Supplemental Figure S3). The peaks of PCT and WBC (inverted) were seen 9.2 ± 10.6 and 4.1 ± 1.3 days respectively after symptom onset. In contrast, peak LDH and CRP occurred at symptom onset (at −0.3 ± 1.0 days and −0.5 ± 0.8 days, respectively). Peaks values for PCT, WBC, LDH, and CRP were 0.295 ± 0.061 ng/mL, 4.1 ± 1.3 × 10⁹/L, 314 ± 104 mmol/L, and 40.8 ± 30.4 mg/L, respectively. Minimum neutrophil and lymphocyte counts were 2.4 ± 1.1 × 10⁹/L at 3.2 ± 5.9 days and 1.1 ± 0.4 × 10⁹/L at 2.6 ± 6.2 days after symptom onset, respectively.

In this early disease cohort, CT opacities and certain labs colocalized and peaked very near the day of symptom onset. More sequential data points were available for WBC and PCT (average of 3.7 tests per patient), and therefore the same methodology for curve formation was applied as that for CT analysis. The dynamic curves of LDH and CRP however required data aggregation and pooling to extrapolate curves based upon pooling of different patients’ data, due to the limited data points available for individual patients (average 1.2 data point per patient). Therefore, 3-day increments were aggregated and averaged until the 10th day after symptom onset for the first points, and then all data points over 10 days were aggregated to derive the last point of the curve.

**Correlation analysis.** A correlation analysis between CT findings and laboratory measurements found a strong correlation between LDH and percent lung opacity (r = 0.68, p = 0.03) and percent GGO (r = 0.65, p = 0.04), between CRP and opacity attenuation (r = 0.60, p = 0.01) and GGO attenuation (r = 0.70, p = 0.003), and between lymphocyte percentage and percent lung opacity (r = −0.26, p = 0.05) and percent consolidation.
(r = −0.31, p = 0.02). A correlation diagram heat map of all investigated CT features and laboratory measurements and a detailed correlogram of features with strong correlation coefficients low probability coefficients are given in Fig. 5.

Referencing dynamic curve for percent lung opacity in one patient. Mapping a single pre-selected external example patient to the CT reference curve for mild COVID-19 disease demonstrated the feasibility of using the dynamic curve as a clinical reference tool to display clinical course severity over time (Fig. 6). Deviation of the CT percent opacity from the reference curve for mild disease is shown in one example, with limited
significance. This applied example of pre-selected severe disease in an independent sight-unseen demographic within another outbreak setting is displayed as a deviation from the generalized curve for mild to moderate disease. External validation with correlative outcomes was not performed. An applied example is presented for dynamic lab and imaging referencing to generalized curves, to show theoretical applied use of such curves (Supplemental video).

**Discussion**

Clearer definition of the clinical manifestations of COVID-19 over time could provide an essential reference point and measurement system for future applied studies. CT opacities pre-dated symptom onset in COVID-19 by an average of three days in this highly selected cohort of early disease in a high prevalence outbreak setting. Opacity volume, subtype and attenuation curves follow a parallel pattern to key clinical and laboratory factors.

In this study, the high number of CT scans per patient (average = 4.2) adds strength to the sequential CT temporal

| Table 1. Data used to generate the dynamic curves for percent lung opacity. |
|---------------------------------------------------------------|
| **Day** | **% Lung involvement** | **Average** | **SD** | **Average** | **SD** | **# Of patients** |
|---------|-------------------------|------------|-------|------------|-------|------------------|
| **Total % Lung opacity** | First CT Scan | −3.4 | 2.2 | 4.1 | 4.3 | 29 |
| | Maximum Opacity | 0.6 | 3.1 | 6.3 | 5.0 | 29 |
| | Next CT after maximum opacity | 6.3 | 5.6 | 5.2 | 4.8 | 18 |
| | Minimum opacity/last CT | 45.8 | 13.1 | 1.1 | 2.5 | 25 |
| **% GGO Lung involvement** | First CT Scan | −3.4 | 2.2 | 3.6 | 4.0 | 28 |
| | Maximum % GGO | 0.7 | 4.1 | 5.1 | 4.5 | 28 |
| | Next Scan | 8.2 | 5.7 | 4.4 | 4.1 | 17 |
| | Minimum % GGO/last CT | 43.6 | 16.5 | 1.0 | 2.3 | 25 |
| **% Consolidation Lung involvement** | First CT Scan (with consolidation) | −3.4 | 2.2 | 0.6 | 0.7 | 27 |
| | Maximum % GGO | 1.3 | 3.0 | 1.9 | 1.2 | 26 |
| | Next Scan | 7.3 | 5.8 | 0.7 | 0.8 | 16 |
| | Minimum % GGO/last CT | 33.0 | 19.1 | 0.1 | 0.1 | 23 |

**Figure 3.** 3D model display of the evolution of COVID-19 opacities of 34 years old male from pre-symptomatic stage to convalescence. Symptom onset is day 0. Green shows 3D whole lung segmentation (derived from an AI model), blue shows GGO lesions, and red shows consolidation. The opacity volume (blue plus red) divided by the whole lung volume (green) is the percent lung opacity. Note normal hilar anatomy (dark green).
analysis model. Prior serial CT analyses have generally not included > 2 multiple CTs in the same patient, as seen here. A reference curve built upon same-patient data is useful to patients with even just one CT at various timepoints in the disease course. In June 2020 the World Health Organization (WHO) clarified indications for imaging as when: PCR is unavailable or delayed, PCR is negative but with a high index of suspicion, patients at high risk, over 60 years old, or with comorbidities, for triage to ward or ICU, hospitalized patients who progress or are unresponsive to therapies, as well as patients with suspicion for pulmonary embolus or pulmonary fibrosis.
Table 3. Data used to generate the dynamic curves for PCT, WBC, and neutrophil and lymphocyte count.

|                | Day                        | Value                        | # Of patients |
|----------------|----------------------------|------------------------------|---------------|
|                | First laboratory test      | −1.0                         | 27            |
|                | Maximum PCT                | 9.2                          | 28            |
|                | Next lab test after maximum| 13.3                         | 10            |
|                | Last follow-up lab test    | 44.3                         | 17            |
| PCT (× 10⁹/L)  | First laboratory test      | −0.7                         | 26            |
|                | Minimum WBC                | 3.7                          | 27            |
|                | Next lab test after minimum| 6.4                          | 16            |
|                | Last follow-up lab test    | 42.9                         | 19            |
| WBC (× 10⁹/L)  | First laboratory test      | −1.0                         | 27            |
|                | Minimum neut. count        | 3.2                          | 28            |
|                | Next lab test after minimum| 6.8                          | 18            |
|                | Last follow-up lab test    | 42.7                         | 20            |
| Neutrophil count (× 10⁹/L) | First laboratory test | −1.0                         | 27            |
|                | Minimum lymph. count       | 2.6                          | 28            |
|                | Next lab test after minimum| 7.5                          | 21            |
|                | Last follow-up lab test    | 39.7                         | 22            |
| Lymphocyte count (× 10⁹/L) | Early screen (day − 4 to − 2) | −3.0                         | 7             |
|                | Peak (day − 1 to 1)        | −0.3                         | 104           |
|                | Follow-up 1 (day 2 to 4)   | 2.6                          | 5             |
|                | Follow-up 2 (day 5 to 7)   | 6.4                          | 5             |
|                | Follow-up 3 (day 8 +)      | 19.0                         | 9             |
| LDH (mmol/L)   | Early screen (day − 4 to − 2) | −3.4                         | 5             |
|                | Peak (day − 1 to 1)        | −0.5                         | 6             |
|                | Follow-up 1 (day 2 to 4)   | 2.8                          | 9             |
|                | Follow-up 2 (day 5 to 7)   | 6.5                          | 6             |
|                | Follow-up 3 (day 8 +)      | 18.9                         | 9             |
| CRP (mg/L)     | Early screen (day − 4 to − 2) | −3.4                         | 5             |
|                | Peak (day − 1 to 1)        | −0.5                         | 6             |
|                | Follow-up 1 (day 2 to 4)   | 2.8                          | 9             |
|                | Follow-up 2 (day 5 to 7)   | 6.5                          | 6             |
|                | Follow-up 3 (day 8 +)      | 18.9                         | 9             |

Figure 5. Correlation analysis between CT findings and laboratory measurements. (a) Correlation diagram heat map of all investigated CT features and laboratory measurements. Dots are present when p ≤ 0.05 and color represent either a positive (blue) or negative (red) correlation coefficient (r). (b) Detailed correlogram of features with strong correlation coefficients low probability coefficients (low p-values).
This represented an expansion of indications, compared to previous guidelines, enhancing the potential utility of a generalized reference to define an expected or mild disease course. Standardized COVID-19 quantification of chest CT opacities may non-invasively and rapidly characterize disease, which may be valuable to investigate as one element of a composite outcome measure or predictive surrogate endpoint in clinical trials. Sequential CT data presented here informs a generalized dynamic curve that may provide a useful reference for specific patients in a similar setting. Standardization by date of symptom onset allows comparison and characterization of patients who may not yet have declared themselves along a specific disease trajectory. Such comparisons to a generalized curve could theoretically help define risk, triage, resource allocation, or need for timely early medical countermeasures upon deviation from an expected normalized curve for similar patients. Such curves could also clarify presence and degree of chronic lung opacity, which could help decipher chronic lung effects. Residual opacities averaging 1.1% were present at last CT scan (average of 46 days), which raise the concern for residual pulmonary impairment after convalescence, and certainly merit further investigation of chronic effects. Chest CT data in a research or clinical trial setting documents actual lung disease that might be otherwise hidden by clinical trials that only follows secondary effects and externally apparent clinical metrics.

GGOs are known to be the primary lung opacity in COVID-19. In the studied cohorts, consolidation peaked later in the patient course and resolved faster than GGO. Consolidation however is associated with a poorer outcome. This suggests mucous or debris within the alveolar air sacs associated with SARS-CoV-2 may evolve over the course of the infection and this change may be detected with CT. Residual opacity or scarring on CT persisted during convalescence an average of 46 days after symptom onset, which is of unknown significance. Future studies merit evaluation of outcomes associated with consolidation or other combination of patterns, and the potential predictive role for CT AI in triaging into specific treatment tracks.

Figure 6. Demonstration of the utility of the dynamic curve using a pre-selected patient with severe COVID-19. Percent lung opacity was calculated from 3 serial chest CT’s. Deviation from the mild to moderate disease curve occurs 9 days after symptom onset, as a clinical “red flag”.

With contextual and temporal referencing, CT data may define when and how a patient’s disease course might vary or diverge from that expected for an uncomplicated recovery (Fig. 6). CT could potentially also play an enhanced role in clinical trials by defining reproducible response criteria for triage, prognostication, or clinical alerts in the context of comparison to a standard dynamic curve or “reference nomogram”. The speculative potential for such a tool may support development of a quantification tool as a part of the evaluation of similarly infected patients (with comparable variables of community prevalence, age, underlying lung disease or comorbidities, etc.).

Symptom and RT-PCR screening remain key metrics for re-opening or back to work (or school) strategies. The potential role of imaging has evolved over the course of the pandemic, however no consensus exists on exact utility. In the event that RT-PCR testing is unavailable, delayed, or clinically suspected to be false negative, then imaging may play a role in the diagnosis of COVID-19. The WHO suggests not using chest imaging for diagnosis in asymptomatic contacts of patients with COVID-19. However, 27 of 29 patients here with contact or travel history had CT opacities averaging 3.4 days before symptom onset. Also, given the recent confusion over testing in the asymptomatic population, the fact that chest CT here showed infiltrates before symptoms developed merits further consideration. This is especially relevant, given the unmet need for evidence to guide...
testing and imaging recommendations that are currently rated as low level of evidence, resulting in skepticism, heterogeneity of practice, and confusion.

The dataset presented here was somewhat atypical, in that almost all patients received CT and laboratory tests before symptoms developed. The poorly defined pre-symptomatic phase of the SARS-CoV-2 infections was explored here with CT and laboratory findings. Prior studies with CT data have pooled intervals and patients in order to generate curve estimates. In comparison, the present study utilizes multiple sequential CTs from the same patient in order to generate a higher fidelity dynamic curve, without the screening bias present from pooling data among patients.

Prior case reports have attempted to define patient-specific curves with serial CT. Pan et al. used a CT score based on the sum of each lobe score calculated from a range of percent involvement, and therefore grouped patients with different severity. In addition, their survivor group presented a great heterogeneity in patients’ severity with patients presenting CT severity score from 0 to 20. We feel that the use of total lung involvement percent might be more objective and reproducible way to describe severity, and less subject to reader subjectivity. Peak CT opacities on the day of symptom onset is a markedly different finding than seen on previous studies, one of which reported a peak CT opacity 10 days post-symptom onset. One possible explanation is patient selection bias. The cohort presented here may be relatively healthy with early disease and early CT targeted testing practices, in a high prevalence outbreak setting, perhaps with light viral exposure loads, although speculative. The extent of disease may be correlated with the viral exposure levels and times, thus it is possible that other reports describe patients who are sicker, presented a higher viral load or simply were selected for CT only when they became increasingly ill. This last bias speaks to the variability in the timing of CT either early or later as a critical care tool, for patients who do not improve in expected timeframes. Differences in methods dilutes individual patient dynamics and may explain why peak disease date is reported to be different in other studies.

Data aggregation and pooling certainly limit the reproducibility and reliability of those curves. Labs peaked close to the onset of symptoms and colocalized with peak opacities. Even though this methodology was based on only a few longitudinal datasets (8/20 for LDH), it has been widely used previously to display this type of sparse data.

This study is further limited by its retrospective nature and multiple major patient selection biases, which may preclude extrapolation to other patient populations. The total number of CTs (n = 121) and sequential laboratory tests (n = 105) is substantive, however 29 patients is a relatively small study. This single center study in a high prevalence setting limits generalizability or extrapolation to dissimilar or heterogeneous demographics. CTs were also not taken at standard times or uniform intervals with reference to symptom onset, and 2/29 had no CT before symptom onset. Awareness of outbreak and exposures may have lowered the threshold for presentation. The dynamic curves contain several underlying assumptions about the normalization of the data over time in order to construct a curve with intermediate points. Backfitting the pre-symptomatic curves to a known pre-symptomatic normal/zero disease is somewhat arbitrary, based upon historical average serial interval of SARS-CoV-2, which could make the pre-symptomatic curve unreliable when applied as a reference. The segmentation process focused on attenuation thresholds which separated consolidation from ground glass segmentations and included small intra-parenchymal vessels in both. The effect was not analyzed independently.

Clinical utility of the laboratory curves remains undefined. However, it is possible although speculative that the dynamic radiographic and laboratory curves together might be useful as reference for clinical triage for borderline patients as an extra factor in support of increased level of acute care (Supplemental video). Dynamic reference curves may inform the relative disease status of positive SARS-CoV-2 patients, in relation to the expected course of mild disease. For example, if a patient's CT data point resides within the dynamic reference curves, then mild disease may be likely, and the patient might be expected to improve during convalescence. In this way, a derived percent lung opacity on CT is a window into the clinical course, with severity of disease expressed as graphical deviation from a generalized curve. Although speculative, if the CT data point maps well outside the reference curve, then the patient deviating from mild disease might require consideration of more advanced or critical care. One example patient was selected for having advanced disease and serial chest CTs, and was plotted in comparison to the generalized curve for opacities, in order to show this point. The disease course in this example case demonstrates how the reference curves might function to define deviation, in a similar fashion to plotting an infant's or toddler's height and weight percentile to identify deviations from normal (Fig. 6). This single pre-selected case was specifically chosen to demonstrate the ability of the reference curves to alert for deviation from mild disease. However, this work without further prospective studies does not prove anything besides feasibility.

In conclusion, COVID-19 opacities were observed multiple days prior to symptom onset, culminated on the day of symptom onset and slowly decreased during follow-up in an initially asymptomatic cohort with early and mild to moderate COVID-19. Compared to GGOs, consolidation peaked later and almost resolved quicker in this cohort. Metrics for comparison could provide valuable clinical reference data for early detection of deviation from the expected disease course, which could potentially inform early medical countermeasures, therapeutic decision making, or clinical trial response criteria. Characterization of correlative patterns in such readouts can potentially identify patients with COVID-19 pneumonia by defining extreme deviations from standardized curves for patients with mild disease. Certainly a better understanding of serial disease changes on CT and labs...
over time could enlighten healthcare decision-makers facing off against an incompletely understood and novel virus in the context of medical countermeasures, chronic lung effects, or mutational variants.

**Methods**

**Subjects.** Xiangyang NO.1 People’s Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China (Approval #20200702150947) and University of Milan (Università Degli Studi Di Milano) Research Board/Institutional Review Board (IRB), Milan, Italy (#324-2020 and 562-2020 and #335-2020), provided approval for this study. The study was conducted in accordance with the local IRB and ethics approval for retrospective evaluation and data sharing. Informed consent requirements were waived by both Xiangyang No. 1 People’s Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China (Approval #20200702150947) and University of Milan (Università Degli Studi Di Milano) Research Board/IRB, Milan, Italy (#324-2020 and 562-2020 and #335-2020), due to the nature of the retrospective observational study.

Patients were retrospectively selected from a larger cohort of 739 patients who underwent initial CT screening alongside RT-PCR on the day of presentation at point of care settings in Hubei Province, China. 710 patients had only one CT. 29 patients who received 2 or more chest CTs over the course of their care during the initial hit phase of the pandemic were identified and analyzed for this study. All patients were RT-PCR positive for SARS-CoV-2. CT and laboratory tests were conducted between January 21, and April 12, 2020.

All 29 patients underwent screening with chest CT either because of a history of contact with patients with proven or suspected COVID-19 or because of high exposure risk due to travel in high prevalence regions (outbreak zones). The patients were predominately female (69%, 20/29), and were 41 ± 10 years old (range 25 to 60 years old). The hospitalization period was 15 ± 4 days and the symptomatic period was 10 ± 2 days. The overall follow-up period, defined as the time from first CT or laboratory measurement to last CT or laboratory measurement, was 50 ± 16 days (range 6 to 69 days). Demographic data, symptoms, and follow-up period is given in Table 4. The day of symptom onset was defined as day 0. Symptom onset was defined as the presence of fever (body temperature ≥ 37.8 °C) and one or more of the following: fatigue, headache, nasal discharge, sore throat, cough, myalgia, diarrhea, nausea or vomiting. Twenty-seven of 29 patients had a CT prior to symptom onset. No patients had a poor outcome or advanced disease requiring intervention. None of the 29 patients had a poor outcome or required intervention throughout the course of disease.

**CT acquisition.** Non-contrast chest CT was obtained with 120 kVp (Toshiba and GE Healthcare). The scans were reconstructed as axial images with 0.873 × 0.873 mm pixel size and 512 × 512 matrix with a standard slice thickness of 5 mm.

**CT interpretation.** For each patient, initial chest CT was obtained on the day of presentation and subsequent sequential CT scans were obtained in intervals during a follow-up of 2 to 69 days after the initial scan (average 43 ± 20 days). Two radiologists, blinded to the clinical and laboratory data, retrospectively and independently reviewed each CT for the presence and location of opacities, type of opacity (GGO, consolidation, intralobular septal lines (“crazy paving”)), atelectasis, sub-pleural reticulation, mosaic attenuation, number of distinct opacities, upper/lower and peripheral/central location of the opacities, presence of pleural effusion.

| Table 4. Demographic data and follow-up periods for patients with sequential CTs and COVID-19. |
| --- |
| Number | Percent |
| Female sex | 20 | 69 |
| Chinese nationality | 29 | 100 |
| Smoker | 17 | 59 |
| Contact or suspected contact with COVID-19 Pt | 29 | 100 |
| Most common symptoms | | |
| Fever (temperature ≥ 37.8 °C) | 7 | 24 |
| Fatigue | 3 | 10 |
| Myalgia | 3 | 10 |
| Nasal discharge or obstruction | 3 | 10 |
| Sore throat | 3 | 10 |
| Cough | 3 | 10 |
| Age, years | 41 ± 10 | 25 | 60 |
| Symptomatic period, days | 15 ± 4 | 10 | 29 |
| Number of CTs | 4.2 ± 1.6 | 2 | 8 | 121 |
| Number of lab tests | 4.4 ± 1.6 | 1 | 7 | 129 |
| Total follow-up, days | 50 ± 16 | 6 | 69 |
| CT follow-up range, days | 44 ± 20 | 2 | 69 |
| Lab follow-up range, days | 32 ± 23 | 0 | 69 |
bronchial wall thickening, tree-in-bud nodules, and pre-existing lung disease (including emphysema, bronchiectasis, and fibrosis). All discrepancies were resolved by consensus review (174 out of 1815 entries).

Three radiologists manually annotated and segmented lung opacities (www.itksnap.org, www.slicer.org), and differentiated opacity subtypes of GGO and consolidation. Semi-automated (part manual) or assisted segmentation was based on a Hounsfield Unit (HU) attenuation threshold initially, which was subsequently refined manually. The optimal threshold was manually defined between − 400 and − 300 HU. Volume and average density were extracted for: (1) overall opacity, (2) GGO alone, and (3) consolidation alone. Other opacities listed in “CT Findings” including atelectasis and subpleural reticulations, contributed to overall opacities but were not independently segmented. Healthy lung was segmented using a manual threshold set between − 750 and − 650 HU, in order to extract the normal lung.

**Deep learning model.** All chest CTs underwent automated whole lung segmentation using AI tools based on deep learning via a deep neural network model. The lung segmentation model was trained using a previously described model based upon an AH-Net architecture and is publicly available as a part of the NVIDIA Clara Train SDK on NGC (NVIDIA Clara Train SDK v3 2020: https://docs.nvidia.com/clara/tlt-mi/clara-train-sdk-v3.0/index.html#). The extent of lung involvement was determined by combining manual and AI-based segmentation. Opacity volume (segmented manually) was divided by the overall lung volumes (segmented by AI model) to calculate percent lung involvement or percent COVID-19. AI-derived total lung segmentations were reviewed and verified by two radiologists.

**Dynamic curves of COVID-19 percent lung opacity and opacity attenuation.** Dynamic curves for percent COVID-19 lung opacity and opacity attenuation were generated using a maximum of 4 points, including: (1) the first pre-symptomatic CT, (2) the maximum percent opacity/lesion attenuation, (3) the next subsequent CT, and (4) the last follow-up CT. These timepoints reflect relevant points during the disease progression, including: (1) initial point of care at a timepoint nearest to the first suspected risk event such as travel or contact with COVID-19 infected individual, (2) near or at symptom onset, (3) one week after symptom onset, (4) approximately one month after convalescence. The generalized function over time was created using a smoothed polynomial curve between points. The number of patients that were included in the generation of the curves is noted in the tables. To make the curve continuous, the day of infection was assumed to be 5 days prior to the known day of symptom onset. 26-32

**Laboratory data.** All laboratory tests were assessed at admission or early in the disease and, for some measurements, also during follow-up between 1 and 69 days after initial measurements (average 36 ± 22 days). Measurements included 20 different labs: Blood Urea Nitrogen, Creatinine, Aspartate transaminase, Alanine transaminase, Bilirubin, Lactate Dehydrogenase (LDH), Albumin (Alb), C-reactive Protein (CRP), Uric Acid (UA), Procalcitonin (PCT), Red Blood Cell (RBC), Hemoglobin (Hb), Platelet (Plt), White Blood Cell (WBC), Neutrophil, Lymphocyte, Monocyte, Eosinophil percentage and count, Activated Partial Thromboplastin Time (APTT), and Prothrombin time and International Normalized Ratio (PT(INR)). 279 individual laboratory measurements were analyzed during the course of disease in the 29 patients. Twenty-six of 29 patients had laboratory tests prior to symptom onset.

**Dynamic curves of laboratory data.** We analyzed all 20 laboratory measurements and identified PCT, WBC, LDH, and CRP for modeled curves. These dynamic curves for laboratory measurements were done in 2 fashions. For laboratory measurements that were taken an average of 3 or more times per patient during follow-up (PCT and WBC), laboratory curves were built similar to the opacity curves. Up to 4 data points were similarly defined, including: (1) the first laboratory measurement (2) the laboratory measurement of maximum or minimum value (depending on the trend), (3) the next subsequent laboratory measurement, (4) the last follow-up laboratory measurement.

In addition, for measurements that had two or fewer tests per patient (LDH and CRP), data were aggregated and averaged in 3-day increments until the 10th day after symptom onset. For these data, the curve was built from average laboratory values from the following days: (1) early screening: day − 4 to − 2, (2) at symptom onset: day − 1 to 1, (3) follow-up 1: day 2 to 4, (4) second follow-up: day 4 to 6, (5) third follow-up: day 8 and greater.

**Correlation analysis.** To explore the potential relationship between quantitative CT findings and laboratory test results, a Pearson's correlation analysis was performed. The analysis was performed with CT findings and laboratory tests that were taken on the same day or one day apart.

**Example of referencing to dynamic curve for percent lung opacity.** To demonstrate potential applied clinical utility of these curves, 1 patient from a different country with advanced disease was arbitrarily selected retrospectively from a separate external dataset of patients with SARS-CoV-2 positive PCR who had undergone 3 serial CTs during a severe disease course. This single patient who developed advanced severe disease was retrospectively mapped to, and plotted on, the generalized dynamic reference curve for lung opacity percent over time for patients with mild to moderate disease (Fig. 6).
References

1. Rubin, G. D. et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. *Radiology* 296, 172–180 (2020).
2. Hope, M. D., Raptis, C. A., Shah, A., Hammer, M. M. & Henry, T. S. A role for CT in COVID-19? What data really tell us so far. *The Lancet* 395, 1189–1190 (2020).
3. AKL, E. A. et al. Use of chest imaging in the diagnosis and management of COVID-19: a WHO rapid advice guide. *Radiology* https://doi.org/10.1148/radiol.2020203173 (2020).
4. Kucirka, L. M. et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. *Ann. Intern. Med.* 173, 262–267 (2020).
5. Colombi, D. et al. Well-artered lung on admitting chest CT to predict adverse outcome in COVID-19 pneumonia. *Radiology* 296, E86–E96 (2020).
6. Yu, Q. et al. Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients. *Theranostics* 10, 5641–5648 (2020).
7. Li, K. et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). *Eur. Radiol.* 30, 4407–4416 (2020).
8. Huang, L. et al. Serial quantitative chest CT assessment of COVID-19: deep-learning approach. *Radiol.: Cardiothoracic Imaging* 2, e200075 (2020).
9. Lyu, P., Liu, X., Zhang, R., Shi, L. & Gao, J. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics. *Investig. Radiol.* https://doi.org/10.1097/RLI.0000000000000689 (2020).
10. Yu, N. et al. Lung involvement in patients with coronavirus disease-19 (COVID-19): a retrospective study based on quantitative CT findings. *Chin. J. Acad. Radiol.* https://doi.org/10.1007/s42058-020-00034-2 (2020).
11. Wang, T. et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. *Radiology* 296, E55–E64 (2020).
12. Pan, F. et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). *Radiology* 295, 715–721 (2020).
13. Bernheim, A. et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology* 295, 200463 (2020).
14. Ding, X., Xu, J., Zhou, J. & Long, Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. *Eur. J. Radiol.* 127, 109009 (2020).
15. Chung, M. et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). *Radiology* 295, 202–207 (2020).
16. Sethuraman, N., Jeremiah, S. S. & Ryo, A. Interpreting diagnostic tests for SARS-CoV-2. *JAMA* https://doi.org/10.1001/jama.2020.8259 (2020).
17. Lanza, E. et al. Quantitative chest CT analysis in COVID-19 to predict the need for oxygenation support and intubation. *Eur. Radiol.* https://doi.org/10.1007/s00330-020-07013-2 (2020).
18. Shang, Y. et al. Clinical characteristics and changes of chest CT features in 307 patients with common COVID-19 pneumonia infected SARS-CoV-2: a multicenter study in Jiangsu, China. *Int. J. Infect. Dis.* 96, 157–162 (2020).
19. Cheng, Z. et al. Quantitative computed tomography of the coronavirus disease 2019 (COVID-19) pneumonia. *Radiology of infectious diseases (Beijing, China).* https://doi.org/10.1016/j.rid.2020.04.004 (2020).
20. Liu, F. et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. *Theranostics* 10, 5613–5622 (2020).
21. Sun, D. et al. CT quantitative analysis and its relationship with clinical features for assessing the severity of patients with COVID-19. *Korean J. Radiol.* 21, 859–868 (2020).
22. CDC. Workplace Decision Tool: Workplaces Considerations for Reopening During the COVID-19 Pandemic. *Centers for Disease Control and Prevention.* https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/workplace-decision-tool.html (2020). Date accessed: 16 June 2020.
23. CDC. Overview of Testing for SARS-CoV-2 (COVID-19). Center for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/testing/testing-overview.html (2020). Date accessed: 25 September 2020.
24. Leonardis, A. et al. Role of computed tomography in predicting critical disease in patients with covid-19 pneumonia: a retrospective study using a semiautomatic quantitative method. *Eur. J. Radiol.* 130, 109010 (2020).
25. Pan, F. et al. Different computed tomography patterns of Coronavirus Disease 2019 (COVID-19) between survivors and non-survivors. *Sci. Rep.* 10, 11336 (2020).
26. Wang, Y.-C. et al. Dynamic evolution of COVID-19 on chest computed tomography: experience from Jiangsu Province of China. *Eur. Radiol.* https://doi.org/10.1007/s00330-020-06976-6 (2020).
27. He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.* https://doi.org/10.1038/s41591-020-0869-9 (2020).
28. Kauczor, H. U. et al. Automatic detection and quantification of ground-glass opacities on high-resolution CT using multiple neural networks: comparison with a density mask. *AJR Am. J. Roentgenol.* 175, 1329–1334 (2000).
29. Lee, J. H. et al. High versus low attenuation thresholds to determine the solid component of ground-glass opacity nodules. *PLoS ONE* 13, e0205490 (2018).
30. Matsuguma, H. et al. Objective definition and measurement method of ground-glass opacity for planning limited resection in patients with clinical stage IA adenocarcinoma of the lung. *Eur. J. Cardiothorac. Surg.* 25, 1102–1106 (2004).
31. Ko, J. P. et al. Lung Adenocarcinoma: Correlation Of Quantitative CT findings with pathologic findings. *Radiology* 280, 931–939 (2016).
32. Cohen, J. G. et al. Software performance in segmenting ground-glass and solid components of subsolid nodules in pulmonary adenocarcinomas. *Eur. Radiol.* 26, 4465–4474 (2016).
33. Liu, S. et al. in *International Conference on Medical Image Computing and Computer Assisted Intervention*. 851–858 (Springer, Cham).

Acknowledgements

Work supported by the NIH Intramural Targeted Anti-COVID-19 (ITAC) Program, funded by the National Institute of Allergy and Infectious Diseases. This work was also supported by the Center for International Oncology and the Intramural Research Program of the National Institutes of Health (NIH) by intramural NIH Grants ZI1 1ZID BC011242 and CL040015. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91019F00129.
Author contributions
M.T.K., N.V., and M.B. are equally contributing authors. M.T.K., N.V., M.B., E.T., S.X., F.P., M.C., A.S., E.S., A.M.I., G.C., B.T., B.W. participated in data collection, curation, and image processing. M.T.K., N.V., M.B., S.X., E.T., S.H., A.A., K.S., B.T., B.W. participated in research design. S.X., D.Y., Z.X., H.R., D.X., M.F. performed deep learning models. M.T.K., N.V., M.B., S.K., B.T., B.W. wrote or contributed to the writing of the manuscript. All authors contributed ideas, participated in related scientific discourse and interpretation of results. All authors reviewed the manuscript and approved the final version.

Funding
Open Access funding provided by the National Institutes of Health (NIH).

Competing interests
The content of this publication does not necessarily reflect the views or policies of the National Institutes of Health, the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. MB is a recipient of the 2019 Alain Rahmouni SFR-CERF research grant provided by the French Society of Radiology together with the French Academic College of Radiology. NV is an employee of Philips Research North America. DY, ZX, HR, DX, MF are employees of NVIDIA corp. BW is Principal Investigator on the following CRADA's (Cooperative Research & Development Agreements) between NIH and related commercial partners that involve artificial intelligence and deep learning: Philips Image Guided Therapy (CRADA), Philips Research (CRADA), Philips (CRADA), Siemens (CRADA), NVIDIA (CRADA). All other authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-85694-5.

Correspondence and requests for materials should be addressed to B.J.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021